TY - JOUR
T1 - Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease
AU - Lee, Michelle T.
AU - Mahtta, Dhruv
AU - Chen, Liang
AU - Hussain, Aliza
AU - Al Rifai, Mahmoud
AU - Sinh, Preetika
AU - Khalid, Umair
AU - Nasir, Khurram
AU - Ballantyne, Christie M.
AU - Petersen, Laura A.
AU - Virani, Salim S.
N1 - Funding Information:
Funding: SSV: Department of Veterans Affairs (VA) Health Services Research & Development (HSR&D) Service Investigator Initiated Grant (IIR 16–072), American Heart Association Beginning Grant-in-Aid (14BGIA20460366), American Diabetes Association Clinical Science & Epidemiology award (1-14-CE-44), Houston VA HSR&D Innovations grant (CIN13-413). Conflicts of Interest: MTL, DM, LC, AH, MAR, PS, UK, KN, LAP: None; CMB: Grant/Research Support (paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Esperion, Ionis, Novartis, Regeneron, Roche Diagnostic, NIH, American Heart Association, American Diabetes Association; Consultant: Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Corvidia, Denka Seiken, Esperion, Genentech, Gilead, Matinas BioPharma Inc, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo; SSV: Honorarium, American College of Cardiology (Associate Editor for Innovations, acc.org); Steering Committee, Patient & Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute (no financial remuneration). Authorship: All authors had access to the data and approved the manuscript prior to submission. MTL: Conceptualization, methodology, investigation, writing (original draft & editing), validation, visualization; DM: Conceptualization, methodology, investigation, writing (original draft & editing), validation, visualization; LC: Software, formal analysis, data curation; AH: Writing – review & editing; MAR: Writing – review & editing; PS: Conceptualization, methodology, writing – review & editing; UK: Writing – review & editing; KN: Writing – review & editing; CMB: Writing – review & editing; LAP: Writing – review & editing; SSV: Conceptualization, methodology, investigation, writing - review & editing, validation, visualization, data curation, supervision, project administration, funding acquisition.
Funding Information:
Funding: SSV: Department of Veterans Affairs (VA) Health Services Research & Development (HSR&D) Service Investigator Initiated Grant ( IIR 16–072 ), American Heart Association Beginning Grant-in-Aid ( 14BGIA20460366 ), American Diabetes Association Clinical Science & Epidemiology award ( 1-14-CE-44 ), Houston VA HSR&D Innovations grant ( CIN13-413 ).
Publisher Copyright:
© 2021
PY - 2021/8
Y1 - 2021/8
N2 - Background: Recent literature has shown an association between atherosclerotic cardiovascular disease and inflammatory bowel disease, potentially mediated through chronic inflammatory pathways. However, there is a paucity of data demonstrating this relationship among young patients with premature atherosclerotic cardiovascular disease. Methods: Using data from the nationwide Veterans wIth premaTure AtheroscLerosis (VITAL) registry, we assessed the association between extremely premature and premature atherosclerotic cardiovascular disease (age at diagnosis: ≤40 years and ≤55 years, respectively) and inflammatory bowel disease. Patients were compared with age-matched controls without atherosclerotic cardiovascular disease. Multivariable regression models adjusted for traditional risk factors. Results: We identified 147,600 patients and 9485 patients with premature and extremely premature atherosclerotic cardiovascular disease, respectively. Compared with controls, there was a higher prevalence of overall inflammatory bowel disease among premature (0.96% vs 0.84%; odds ratio [OR] 1.14; 95% confidence interval [CI], 1.08-1.21) and extremely premature (1.36% vs 0.75%; OR 1.82; 95% CI, 1.52-2.17) patients. After adjustment, these associations attenuated in both premature and extremely premature groups (OR 1.07; 95% CI, 1.00-1.14 and OR 1.61; 95% CI, 1.34-1.94, respectively). Conclusion: Inflammatory bowel disease is associated with higher odds of extremely premature atherosclerotic cardiovascular disease, especially for those age ≤40 years. With increasing age, this risk is attenuated by traditional cardiometabolic factors such as obesity, hypertension, diabetes, smoking, and dyslipidemia. Prospective studies are needed to assess the role of early intervention to decrease cardiovascular risk among young patients with inflammatory bowel disease.
AB - Background: Recent literature has shown an association between atherosclerotic cardiovascular disease and inflammatory bowel disease, potentially mediated through chronic inflammatory pathways. However, there is a paucity of data demonstrating this relationship among young patients with premature atherosclerotic cardiovascular disease. Methods: Using data from the nationwide Veterans wIth premaTure AtheroscLerosis (VITAL) registry, we assessed the association between extremely premature and premature atherosclerotic cardiovascular disease (age at diagnosis: ≤40 years and ≤55 years, respectively) and inflammatory bowel disease. Patients were compared with age-matched controls without atherosclerotic cardiovascular disease. Multivariable regression models adjusted for traditional risk factors. Results: We identified 147,600 patients and 9485 patients with premature and extremely premature atherosclerotic cardiovascular disease, respectively. Compared with controls, there was a higher prevalence of overall inflammatory bowel disease among premature (0.96% vs 0.84%; odds ratio [OR] 1.14; 95% confidence interval [CI], 1.08-1.21) and extremely premature (1.36% vs 0.75%; OR 1.82; 95% CI, 1.52-2.17) patients. After adjustment, these associations attenuated in both premature and extremely premature groups (OR 1.07; 95% CI, 1.00-1.14 and OR 1.61; 95% CI, 1.34-1.94, respectively). Conclusion: Inflammatory bowel disease is associated with higher odds of extremely premature atherosclerotic cardiovascular disease, especially for those age ≤40 years. With increasing age, this risk is attenuated by traditional cardiometabolic factors such as obesity, hypertension, diabetes, smoking, and dyslipidemia. Prospective studies are needed to assess the role of early intervention to decrease cardiovascular risk among young patients with inflammatory bowel disease.
KW - Atherosclerosis
KW - Cardiovascular disease
KW - Chronic inflammation
KW - Crohn disease
KW - Premature ASCVD
KW - Ulcerative Colitis
KW - Veterans
UR - http://www.scopus.com/inward/record.url?scp=85105361864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105361864&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2021.02.029
DO - 10.1016/j.amjmed.2021.02.029
M3 - Article
C2 - 33812865
AN - SCOPUS:85105361864
SN - 0002-9343
VL - 134
SP - 1047-1051.e2
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 8
ER -